Home / Market News / $ZBH
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Leerink Partners Adjusts Price Target on Zimmer Biomet Holdings to $110 From $97

Nov 9, 2026, 12:35 PM UTC · Primary ticker $ZBH

Leerink Partners has increased its price target for Zimmer Biomet Holdings from $97 to $110, signaling a more optimistic valuation outlook for the medical technology firm. This analyst upgrade is generally a positive signal for the stock, reflecting improved market expectations.

Leerink Partners has updated its valuation for Zimmer Biomet Holdings, raising the price target from $97 to $110. This adjustment indicates a more favorable outlook from the analyst firm regarding ZBH's future performance and market value. For traders, this is a moderately positive signal in the short term, as it can attract buying interest and potentially lead to a modest price increase. The long-term implications depend on whether the underlying fundamentals support this revised valuation. A key opportunity for traders is to consider if this upgrade reflects broader positive sentiment in the medical technology sector or specific improvements within ZBH.

$ZBH positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.